Exousia Bio, Inc. (LMMY): M&A transaction — Zhang Shengwu acquires 64.29% of LAMY, becomes sole director and CEO

Exousia Bio, Inc.

Zhang Shengwu purchased 5,250,000 shares (64.29% voting control) for $335,910 from Witmer and Townsend.
Dwight Witmer resigned as Director, CEO, CFO, Secretary; Stephen Townsend resigned as Director, COO.
Zhang Shengwu appointed as Sole Director, President, CEO, Secretary; will devote at least 20 hours/week.
Zhang Shengwu is CEO of Shanghai Jiuye Technology Group; former Director of Operations at Dalian Damao Surveying.

item 5.01 item 5.02

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Exousia Bio, Inc. underwent a change of control involving Zhang Shengwu for $335,910 in cash (closed 2024-12-06).

Action: change of control
Counterparty: Zhang Shengwu
Consideration: $335,910 in cash
Closing: 2024-12-06

Exact text from the filing

of the outstanding shares of the Company’s common stock and constitute voting control of the Company. The total consideration paid by Mr. Shengwu for the Acquired Shares was $335,910 in cash, $318,410 to Mr. Witmer and $17,500 to Mr. Townsend. In conjunction with the Change-in-Control Agreements, on December 6, 2024, Dwight Witmer resigned as a Director, CEO,

View on SEC.gov

Browse all m&a transactions →

Exousia Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-24-008767

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.